Morgan, Ryan W.
Karlsson, Michael
Sutton, Robert M.
Kilbaugh, Todd J.
Article History
First Online: 18 April 2017
Compliance with Ethical Standards
:
: Ryan W. Morgan declares that he has no conflict of interest.Michael Karlsson has received salary support from NeuroVive Pharmaceutical AB for work related to traumatic brain injury. NeuroVive Pharmaceutical AB also owns the IP for pre-clinical compounds Dr. Karlsson partially developed at his previous academic institution. Although these compounds could theoretically be useful in the treatment of cardiac arrest, to date, no work whatsoever has been conducted with these compounds related to cardiac arrest.Robert M. Sutton has received speaker’s honoraria from ZOLL and is a member of the Pediatric Research Task Force of the American Heart Association’s Get With The Guidelines®-Resuscitation Registry.Todd J. Kilbaugh declares that he has no conflict of interest.
: This article does not contain any studies with human or animal subjects performed by any of the authors.